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Vancomycin-resistant enterococci (VRE) are important pathogens causing nosocomial
infections, and there is reason for concern about their resistance and great ability to spread in
hospital environments, especially intensive-care units (ICU). To determine the prevalence of
rectal colonization by VRE, and the risk factors associated with their presence, rectal surveillance
swabs were taken from patients under treatment in two intensive-care units (one medical and
another both medical and surgical) at São Paulo Hospital, over a two-year period. Thirty-three
percent of the 147 patients evaluated had VRE.  The only significant variable in the logistic
regression was the length of stay in the ICU.
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Recently, vancomycin-resistant enterococci (VRE)
have become important nosocomial pathogens because
of their rapid spread [1], significant attributable mortality
[2-5], limited options for therapy and risk of transfer
of vancomycin resistance to virulent pathogens, such
as Staphylococcus aureus, prompting the Centers for
Disease Control (CDC) to publish guidelines in 1995
for the control of this pathogen in hospital environments;
methods were suggested for the surveillance of
colonization in the gastrointestinal tract, a major site of
initial colonization. VRE was first isolated in Europe in
1988 [6]; subsequently there have been accounts of
its presence in several other countries around the world.
The percentage of nosocomial VRE infections in
intensive care units (ICUs) reported to the NISS
(Nosocomial Infections Surveillance System) of the
CDC  increased between 1993 and 1998 from 0.4%
to 13.4% [7], and the large, unrecognized population
of patients who are colonized in ICUs are under risk
of progression to infection. Colonization with VRE has
been associated with a variety of factors, including
length of hospital stay, underlying disease (particularly
renal failure and neutropenia), liver transplantation,
severity of illness, the presence of feeding tubes,
proximity to colonized patients and antibiotic exposure,
in particular treatment with certain antibiotics (e.g.,
cephalosporin, drugs with activity against anaerobic
bacteria and vancomycin) [8,9]. In Brazil, vancomycin-
resistant enterococci (E. faecium) were initially
described in 1996 in Curitiba, in a child with medullar
aplasia [10]; consequently, surveillance cultures began
to be adopted by various hospitals, in keeping with
guidance from the CDC [11]. At our hospital, VRE
(Enterococcus faecalis) was isolated for the first time
in January 1998, from a surveillance rectal swab culture
from a 23-year-old woman with Acute Lymphocytic
Leukemia (ALL) [12]. Following this initial isolation,
VRE began to be isolated continuously in surveillance
rectal swabs at our general ICU, and it became, as in
the rest of the world, a reason for concern for the
hospital infection-control service staff, calling for the
implementation of isolation and guidance measures in
hospital communities. We began a surveillance study
of these patients, endeavoring to define the prevalence
of rectal colonization and associated risk factors in two
www.bjid.com.br
BJID 2005; 9 (February) 65
ICUs (one medical and one medical-surgical), over a
two-year period.
Material and Methods
São Paulo Hospital is a 660-bed  tertiary school
hospital, belonging to the Federal University of São
Paulo, located in the city that is their namesake. Two
ICUs were selected for the performance of weekly
rectal surveillance swabs one was a medical and surgical
ICU, with 16 beds and the other was a medical
(pulmonary care) unit, with six beds. The study was
done from January 2000 through December 2001.
All patients with over three days stay in the ICUs
were submitted to rectal surveillance swabs and to
weekly observation of rectal colonization. The swabs
were sent to the Special Clinical Microbiology
Laboratory and plated on a screening BHI plate
containing 6µg/mL vancomycin and incubated at 37ºC
for 24 hours. A Gram’s stain was performed and Gram-
positive cocci were detected and subcultured on non-
selective sheep blood agar. Identification was made by
conventional methods proposed by Facklam and Collins
[13]. Antimicrobial sensitivity was evaluated by disk
diffusion and E-test (AB BIODISK, Solna, Sweden)
methods [14]. An MIC for vancomycin =  32 µg/mL
was considered  resistant.  Variables (listed in Table 1-
3) were defined to evaluate the risk factors associated
with VRE contracted in the ICUs. The data was analyzed
using SPSS software (Version 10.0; SPSS Inc., Chicago,
Il.). Continuous data was analyzed using the Student’s t
test. Categorical data was assessed using Pearson’s chi-
square test. A P value of less than .05 was considered
significant. The hospital’s Institutional Review Board
approved the study’s protocol.
Results
A total of 265 swabs were obtained from 147
patients.  Forty-eight patients had VRE-positive swabs,
giving a positive rate of  32.6 %; 10 patients in this
group were positive in clinical cultures (20%),
confirming hospital infection by CDC standards [15].
In the clinical ICUs, 23 swabs were gathered, 9 of
which were positive, reflecting a prevalence of 39%.
In the medical-surgical ICU, 124 swabs were obtained;
39 were positive, with a  prevalence of 31%. A total of
32 variables were studied, of which 27 were categorical
and 5 continuous (Table 1). The significant variables
(p<0.05) were submitted to a multiple logistic
regression, the results of which were as follows: prior
hospitalization (p= 0.04), number of isolated bacteria
(p=0.02), nosocomial infection (p=0.01), length of
hospital stay (p=0.002), length of ICU stay (p< 0.001)
and period under antibiotic treatment (p=0.001). The
only significant variable in the multiple logistic regression
was the length of ICU  stay,  with an Odds Ratio (CI95)
of 4.5 (1.7-7.3, p=0.001).
Discussion
Vancomycin-resistant Enterococci are currently one
of the pathogens of utmost prominence in hospital-
infection control, mostly due to their particular features:
long-lasting colonization of the gastrointestinal tract,
difficult decolonization and great ability for
environmental colonization, facilitating their spread in
hospital environments, notably in ICUs.
We evaluated the extent of colonization with VRE
at two ICUs in a teaching hospital in São Paulo;  the
only risk factor significantly associated with VRE in
patients under intensive-care conditions was the length
of stay in the ICU. Edmond et al.[16] reported various
risk factors for contracting VRE: extended
hospitalization, ICU hospitalization, transplantation,
hematological disease and use of antibiotics. Byers et
al.[17], during an epidemic period, found 6%
colonization in ICUs and wards, indicating as risk
factors: proximity to an unisolated case of VRE,
polytraumatism and use of metronidazol. We did not
find association of VRE with the use of  metronidazol
or any other antimicrobial drug, though it was reported
in other studies [18,19].
Published reports support the hypothesis that after
VCE are introduced, the rates of colonization and
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Table 1. Univariate analysis of Vancomycin-resistant Enterococci prevalence (percentages are given in parentheses)
Rectal Vancomycin-Resistant Enterococci Colonization in Two ICUs
Variable Class Swab + (48) Swab – (99) p
Sex Male 23 (47.9) 58 (58.6) 0.22
Female 25 (52.1) 41 (41.4)
Outcome Death 33 (68.7) 63 (63.6) 0.54
Discharge 15 (31.2) 36 (36.4)
 Prior hospitalization No 23 (47.9) 65 (65.7) 0. 04
Yes 25 (47.9) 34 (34.3)
Diagnosis Medical 18 (37.5) 44 (44.4) 0.42
Surgical 30 (62.5) 55 (55.6)
Parenteral nutrition No 40 (83.3) 88 (88.9) 0.34
Yes 8 (16.7) 11 (11.1)
Arterial catheter No 29 (60.4) 54 (54.5) 0.50
Yes 19 (39.6) 45 (45.4)
Central venous catheter No 4 (8.3) 4 (4.0) 0. 28
Yes 44 (91.7) 95 (95.9)
Nasogastric-enteral tube No 3 (6.2) 3 (3.0) 0.35
Yes 45 (93.7) 96 (96.9)
Tracheal intubation No 3 (6.2) 3 (3.0) 0.35
Yes 45 (93.7) 96 (96.9)
Hemodialysis No 45 (83.3) 92 (92.9) 0.07
Yes 8 (16.7) 7 (7.07)
Swan-Ganz catheter No 34 (70.8) 72 (72.7) 0.81
Yes 14 (29.2) 27 (27.3)
Antiacid use No 0 (0.0) 4 (4.0) 0.15
Yes 48(100.0) 95 (95.9)
Blood Transfusion No 7 (14.6) 21 (21.2) 0.33
Yes 41 (85.4) 78 (78.8)
Immunosupressive drug No 45 (93.9) 92 (92.9) 0.85
Yes 3 (6.2) 7 (7.1)
Corticosteroid No 16 (33.3) 48 (48.5) 0.08
Yes 32 (66.7) 51 (51.5)
Thoracic- abdominal surgery No 34 (70.8) 66 (66.7) 0.61
Yes 14 (29.2) 33 (33.3)
Isolated bacteria Up to 1 24 (50.0) 69 (69.7) 0.02
> 2 24 (50.0) 30 (30.3)
Vancomycin No 12 (25.0) 37 (37.4) 0.13
Yes 36 (75.0) 62 (62.6)
 1st/2nd generation Cephalosporin No 39 (81.2) 79 (79.8) 0.83
Yes 9 (18.7) 20 (20.2)
 3rd/4th generation Cephalosporin No 11 (22.9) 22 (22.9) 0.92
Yes 37 (77.0) 77 (77.8)
Carbapenens No 23 (47.9) 60 (60.6) 0.14
Yes 25 (52.1) 39 (39.4)
Antianaerobic drug No 26 (54.2) 58 (58.6) 0.61
Yes 22 (45.8) 41 (41.4)
Nosocomial infection No 14 (29.2) 51 (51.5) 0.01
Yes 34 (70.8) 48 (48.5)
Cancer No 36 (75.0) 73 (73.7) 0.87
Yes 12 (25.0) 26 (26.3)
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infection increase and vancomycin-resistant enterococci
become endemic unless effective control measures are
introduced [20,21].
Ostrowski et al.[22] in an endemic period on the
presence of VRE in a surgical ICU, found 12%
colonization and the following risk factors: use of second
and third generation cephalosporin, length of hospital
stay, plus ICU hospitalization and solid-organ
transplants. Advanced studies performed in ICUs, both
in epidemic and endemic periods, have shown that cross
contamination is the principal mechanism of VRE
transmission [23,24].  This is one of the few reports of
occurrence during an endemic period, but it indicated
a lower colonization percentage than in our study, which
was 32.6 %. Warren et al.[25], analyzing VRE
epidemiology in a medical ICU, found as risk factors
for colonization: hospitalization for over three days prior
to ICU admission, chronic dialysis and having been
admitted to the hospital once, twice or more over the
previous 12 months.
VRE are important multidrug-resistant opportunistic
pathogens in the hospital environment that are
maintained by the selective pressure of widespread use
of broad-spectrum antimicrobial drugs; they survive on
the hands of health care workers and on inanimate
objects [26]. VRE have been found in the stool of
colonized patients, sometimes for extended periods.
Effective control of VRE should address several
factors, including judicious use of antibiotics, particularly
vancomycin, cephalosporins and drugs with
antianaerobic activity [11]. Patients who are infected
or colonized with VRE should be isolated, preferably
in private rooms. Some authors have suggested placing
patients colonized or infected with VRE together [27].
Adherence to good handwashing procedures is critical
unfortunately it is an area of infection control in which
compliance is chronically deficient [9].
In 1995, the CDC recommendations to prevent the
emergence and spread of vancomycin-resistant
enterococci included the identification and isolation of
patients colonized with vancomycin-resistant
enterococci, hand washing by health care workers and
cleaning of the environment [11]. After identification of
the first case of VRE at our hospital in 1998 [12], the
Hospital Epidemiology Committee began surveillance
rectal cultures at two ICUs in order to identify and
isolate patients who are colonized with VRE and
consequently reduce the transmission of these strains
to other patients.
We found a  high prevalence of  VRE colonization
among the ICU patients (32.6 %); orientations
concerning adherence to good handwashing
procedures, isolation precautions and rational use of
antibiotics were given to ICU personnel and repeated
regularly   after our study.  Educational classes on the
importance of VRE were given in  group sessions, and
Table 2. Univariate analysis of factors associated with Vancomycin-resistant Enterococci
Table 3. Multivariate analysis of Vancomycin-resistant Enterococci cases
Rectal Vancomycin-Resistant Enterococci Colonization in Two ICUs
Variable Swab + (48) Swab – (99) p
Mean (range) Mean (range)
Age (years) 54.5 (14-88) 60.0 (15-91) 0.53
 Length of hospital stay (days) 24.0 (6-124) 15.0 (4-92) 0.00
Length of ICU stay (days) 19.0 (4-124) 11.0 (1-68) < 0.05
Time under antibiotics (days) 20.5 (2-113) 13.0 (1-88) <0.05
Number of antibiotics 4.0 (1-8) 4.0 (1-7) 0.06
Variable Odds ratio (CI95) p
Length of ICU stay 4.5 (1.7 – 7.3) 0.0012
CI = confidence interval.
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guidelines were posted in each unit. We emphasize the
growing importance of the vancomycin-resistant
enterococci as nosocomial pathogens, causing, besides
colonization, severe infections, such as bacteremias,
urinary-tract and surgical-site infections [3,28]. The
therapeutic arsenal presently available is quite scarce,
with accounts of resistance to recently developed drugs
(e.g. linezolide) [29]; there is also concern over the
spread of resistance to Staphylococcus aureus through
the vanA gene, recently described in the U.S. [30].
Continuous surveillance of this pathogen is thus required
in hospital environments, especially in critical units,
where high prevalence generally occurs, to avoid its
progressive spread in hospitals, mainly those with
unreported prior isolation. Surveillance of
gastrointestinal-tract colonization is required, since the
cases diagnosed in clinical cultures account for only
30% of colonized patients [31], and these colonized
patients, as yet lacking clinical symptoms, are the main
VRE disseminators in the hospital environment.
In summary, we found a high rate of VRE
colonization at our ICUs, emphasizing the importance
of length stay in the ICU as a risk factor for rectal
colonization; these data made ICU personnel aware
of  the importance of  infection control measures,
including  hand hygiene, isolation precautions, rational
use of  antimicrobial drugs, as well as rectal colonization
surveillance, in order to decrease VRE prevalence .
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